Serina Therapeutics (SER) Debt to Equity (2017 - 2025)
Serina Therapeutics (SER) has disclosed Debt to Equity for 9 consecutive years, with $1.81 as the latest value for Q3 2025.
- Quarterly Debt to Equity rose 324.59% to $1.81 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.81 through Sep 2025, up 324.59% year-over-year, with the annual reading at -$0.48 for FY2022, 56.85% up from the prior year.
- Debt to Equity hit $1.81 in Q3 2025 for Serina Therapeutics, up from -$0.81 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $1.81 in Q3 2025 to a low of -$1.2 in Q1 2021.
- Historically, Debt to Equity has averaged -$0.66 across 5 years, with a median of -$0.94 in 2023.
- Biggest five-year swings in Debt to Equity: crashed 1112.26% in 2024 and later soared 324.59% in 2025.
- Year by year, Debt to Equity stood at -$1.11 in 2021, then surged by 56.85% to -$0.48 in 2022, then soared by 86.13% to -$0.07 in 2023, then crashed by 1112.26% to -$0.81 in 2024, then skyrocketed by 324.59% to $1.81 in 2025.
- Business Quant data shows Debt to Equity for SER at $1.81 in Q3 2025, -$0.81 in Q3 2024, and -$0.68 in Q2 2024.